|Daily Range||$27.75 - $28.72|
|52-Week Range||$14.31 - $38.48|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||273,374|
|Current FY EPS||$1.22|
Enanta Pharmaceuticals, Inc. (ENTA) Description
Enanta Pharmaceuticals, Inc. Website: http://www.enanta.com/
News & Commentary
Enanta shares sink after a rival hepatitis-C drugmaker delivers phenomenal late-stage results. Is now the time to buy Enanta or flee?
From great clinical results to a big buyout, Enanta, Given Imaging, and Corcept Therapeutics had humongous weeks.
A lack of economic data sends the broad-based S&P 500 lower on the day, but not before Enanta Pharmaceuticals, Relypsa, and Rambus all advance by double-digits.
Enanta shares soar after AbbVie reports incredible results in treating experienced genotype 1 hepatitis-C patients. Is now the time to sell, or can Enanta continue higher?